We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
bluebird (BLUE) Q3 Loss Narrower Than Expected, Sales Miss
Read MoreHide Full Article
bluebird bio Inc. (BLUE - Free Report) reported a loss of $2.94 per share in third-quarter 2020, narrower than the Zacks Consensus Estimate of a loss of $3.07 and the year-ago quarter's loss of $3.73.
Revenues of $19.3 million missed the Zacks Consensus Estimate of $26 million. The figure grew from $8.9 million in the year-ago quarter.
Shares of the company have decreased 33.3% year to date compared with the industry’s decline of 1.1%.
Quarter in Detail
R&D expenses decreased to $140.4 million from $151.4 million a year ago due to a decline in manufacturing costs.
Selling, general and administrative (SG&A) expenses of $68 million were up from $66.3 million in the year-ago quarter due to costs incurred to support the company’s ongoing operations and growth of its pipeline.
Pipeline Development
The company remains on track to complete the rolling biologics license application (BLA) submission for betibeglogene autotemcel (beti-cel; formerly LentiGlobin for β-thalassemia) in mid-2021.
In September 2020,bluebird and Bristol Myers Squibb (BMY - Free Report) announced that the FDA accepted for Priority Review their BLA for idecabtagene vicleucel (ide-cel; bb2121), the companies’ investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.The FDA set an action date of Mar 27, 2021.
In September 2020, the company announced that its investigational pipeline candidate for sickle cell disease (SCD) gene therapy, LentiGlobin, was granted eligibility to the Priority Medicines (PRIME) program by the European Medicines Agency (EMA).
Emergent’s earnings per share estimates have increased from $6.17 to $8.42 for 2021 in the past 60 days. Shares of the company have increased 82.2% year to date.
ADC Therapeutics’ loss per share estimates have narrowed from $4.37 to $4.32 for 2020 and from $3.19 to $3.08 for 2021 in the past 60 days. Shares of the company have increased 4.1% year to date.
bluebird bio, Inc. Price, Consensus and EPS Surprise
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking. Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
Image: Bigstock
bluebird (BLUE) Q3 Loss Narrower Than Expected, Sales Miss
bluebird bio Inc. (BLUE - Free Report) reported a loss of $2.94 per share in third-quarter 2020, narrower than the Zacks Consensus Estimate of a loss of $3.07 and the year-ago quarter's loss of $3.73.
Revenues of $19.3 million missed the Zacks Consensus Estimate of $26 million. The figure grew from $8.9 million in the year-ago quarter.
Shares of the company have decreased 33.3% year to date compared with the industry’s decline of 1.1%.
Quarter in Detail
R&D expenses decreased to $140.4 million from $151.4 million a year ago due to a decline in manufacturing costs.
Selling, general and administrative (SG&A) expenses of $68 million were up from $66.3 million in the year-ago quarter due to costs incurred to support the company’s ongoing operations and growth of its pipeline.
Pipeline Development
The company remains on track to complete the rolling biologics license application (BLA) submission for betibeglogene autotemcel (beti-cel; formerly LentiGlobin for β-thalassemia) in mid-2021.
In September 2020,bluebird and Bristol Myers Squibb (BMY - Free Report) announced that the FDA accepted for Priority Review their BLA for idecabtagene vicleucel (ide-cel; bb2121), the companies’ investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.The FDA set an action date of Mar 27, 2021.
In September 2020, the company announced that its investigational pipeline candidate for sickle cell disease (SCD) gene therapy, LentiGlobin, was granted eligibility to the Priority Medicines (PRIME) program by the European Medicines Agency (EMA).
Zacks Rank & Stocks to Consider
bluebirdis a Zacks Rank #3 (Hold) stock.
Some better-ranked stocks in the biotech sector are Emergent BioSolutions Inc. (EBS - Free Report) and ADC Therapeutics SA (ADCT - Free Report) . While Emergent carries a Zacks Rank #1 (Strong Buy), ADC Therapeutics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings per share estimates have increased from $6.17 to $8.42 for 2021 in the past 60 days. Shares of the company have increased 82.2% year to date.
ADC Therapeutics’ loss per share estimates have narrowed from $4.37 to $4.32 for 2020 and from $3.19 to $3.08 for 2021 in the past 60 days. Shares of the company have increased 4.1% year to date.
bluebird bio, Inc. Price, Consensus and EPS Surprise
bluebird bio, Inc. price-consensus-eps-surprise-chart | bluebird bio, Inc. Quote
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking. Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>